See more : BlackRock MuniVest Fund, Inc. (MVF) Income Statement Analysis – Financial Results
Complete financial analysis of GRAIL, LLC (GRAL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of GRAIL, LLC, a leading company in the Medical – Diagnostics & Research industry within the Healthcare sector.
You may be interested
- Jagran Prakashan Limited (JAGRAN.NS) Income Statement Analysis – Financial Results
- Travere Therapeutics, Inc. (TVTX) Income Statement Analysis – Financial Results
- TELUS Corporation (TU) Income Statement Analysis – Financial Results
- Peekaboo Beans Inc. (BEAN.CN) Income Statement Analysis – Financial Results
- Onconova Therapeutics Inc. Warrants (ONTXW) Income Statement Analysis – Financial Results
GRAIL, Inc. (GRAL)
About GRAIL, Inc.
GRAIL, Inc., a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was incorporated in 2015 and is based in Menlo Park, California. GRAIL, Inc. operates as a former subsidiary of Illumina, Inc.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 93.11M | 55.55M | 14.61M | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 188.72M | 172.00M | 114.62M | 0.00 | 10.31M | 14.08M |
| Gross Profit | -95.61M | -116.45M | -100.00M | 0.00 | -10.31M | -14.08M |
| Gross Profit Ratio | -102.69% | -209.63% | -684.39% | 0.00% | 0.00% | 0.00% |
| Research & Development | 338.75M | 329.58M | 460.21M | 192.91M | 154.58M | 203.38M |
| General & Administrative | 200.27M | 174.11M | 180.53M | 110.03M | 80.90M | 0.00 |
| Selling & Marketing | 162.29M | 122.33M | 53.53M | 13.47M | 7.68M | 0.00 |
| SG&A | 362.56M | 296.44M | 705.13M | 123.51M | 88.58M | 64.34M |
| Other Expenses | 718.47M | -238.00K | 0.00 | 0.00 | -1.82M | 0.00 |
| Operating Expenses | 1.42B | 626.01M | 1.17B | 318.26M | 243.16M | 267.72M |
| Cost & Expenses | 1.61B | 798.01M | 1.28B | 318.26M | 253.46M | 281.80M |
| Interest Income | 7.95M | 1.74M | 332.00K | 6.14M | 12.43M | 12.55M |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 158.70M | 154.76M | 58.45M | 7.56M | 10.31M | 14.08M |
| EBITDA | -620.90M | -575.57M | -1.21B | -308.73M | -243.14M | -269.42M |
| EBITDA Ratio | -666.88% | -1,057.96% | -8,259.60% | 0.00% | 0.00% | 0.00% |
| Operating Income | -1.52B | -742.46M | -1.27B | -316.30M | -253.46M | -281.80M |
| Operating Income Ratio | -1,627.61% | -1,336.56% | -8,659.61% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 7.75M | 1.50M | 90.00K | 4.17M | 8.41M | 6.56M |
| Income Before Tax | -1.51B | -5.44B | -1.27B | -312.12M | -245.05M | -275.23M |
| Income Before Tax Ratio | -1,619.29% | -9,795.48% | -8,658.99% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | -41.95M | -42.29M | -17.48M | 33.00K | -195.00K | 485.00K |
| Net Income | -1.47B | -5.40B | -1.25B | -312.16M | -244.86M | -275.72M |
| Net Income Ratio | -1,574.23% | -9,719.35% | -8,539.39% | 0.00% | 0.00% | 0.00% |
| EPS | -41.34 | -173.87 | -40.18 | -2.52 | -1.99 | -2.42 |
| EPS Diluted | -41.34 | -173.87 | -40.18 | -2.52 | -1.99 | -2.42 |
| Weighted Avg Shares Out | 31.05M | 31.05M | 31.05M | 123.67M | 123.19M | 114.14M |
| Weighted Avg Shares Out (Dil) | 31.05M | 31.05M | 31.05M | 123.67M | 123.19M | 114.14M |
GRAIL to Present at the Morgan Stanley 22nd Annual Global Healthcare Conference
MENLO PARK, Calif. , Aug. 21, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, today announced that company management will present at the Morgan Stanley 22nd...
Illumina Sees The Light: GRAIL Is Gone, Focus Restored (Rating Upgrade)
Illumina completed the spin-off of GRAIL in June 2024, retaining a 14.5% stake. The company is refocusing on its core DNA sequencing business, targeting high single-digit revenue growth by 2027. Q2 2024 results showed a gross margin of 68% and...
GRAIL Inc. (GRAL) Q2 2024 Earnings Call Transcript
GRAIL Inc. (NASDAQ:GRAL ) Q2 2024 Results Conference Call August 13, 2024 4:30 PM ET Company Participants Bob Ragusa - CEO & Director Aaron Freidin - Chief Financial Officer Joshua Ofman - President Conference Call Participants Tejas Savant - Morgan...
Grail to cut jobs, planned hires for 2024 by about 30%
Cancer test maker Grail said on Tuesday it would reduce existing headcount and planned hires for 2024 by about 30%, as part of its restructuring program.
GRAIL Reports Second Quarter 2024 Financial Results and Provides a Strategic Update
Second Quarter Revenue Grew 43% Year-Over-Year to $32.0 Million Portfolio Prioritization and Corporate Restructure Extends Cash Runway into 2028 MENLO PARK, Calif. , Aug. 13, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect...
GRAIL to Announce Second Quarter 2024 Financial Results
MENLO PARK, Calif. , July 31, 2024 /PRNewswire/ -- GRAIL, Inc. (Nasdaq: GRAL), a healthcare company whose mission is to detect cancer early when it can be cured, announced today that it will issue financial results for the second quarter 2024...
GRAIL Announces First Participant Enrolled in REACH Study Evaluating Clinical Impact of Galleri® Multi-Cancer Early Detection (MCED) Test in the Medicare Population
Community Health Network Has Begun Enrollment of the Prospective, Multi-Center Study to Assess the Real-World Clinical Impact of Galleri ® in Addition to Currently Recommended Cancer Screenings Study Enrollment Includes Focus on Diverse and Underrepresented Populations Costs of Galleri and...
3 Top Cancer Treatment Stocks to Buy Now
Discovering and developing a cancer drug that can treat many types of the disease can be extremely lucrative. Consider that one such drug, Merck's (NYSE: MRK ) Keytruda, generated $25 billion in revenue for the pharmaceutical giant last year.
3 Spinoff Stocks You Should Buy Now: July 2024
Stock spinoffs remain popular with companies wanting to unlock shareholder value. By creating spinoff stocks that will trade independently on the market, corporations believe they can narrow their focus to core operations while the newly public company doesn't get lost in the shuffle of...
GRAIL Advances the Galleri® Registrational Clinical Trial Program
GRAIL Completes Enrollment of More Than 35,000 Participants in the PATHFINDER 2 Study; Results From the First 25,000 Participants Expected in the Second Half of 2025 GRAIL Completes Final Study Visits for the NHS-Galleri Trial; Final Results Expected in 2026...
Source: https://incomestatements.info
Category: Stock Reports